- Jul 2018
-
europepmc.org europepmc.org
-
On 2017 Dec 16, Y Uncu commented:
We would like to state that this comment might be misleading for the readers, since the issues mentioned in the comment has been previously brought into question and extensively evaluated. It was concluded that there is no scientific flaw accordingly. We would be glad to provide further information should the readers require. (yuncu@uludag.edu.tr)
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY. -
On 2017 Dec 08, Nazan Bilgel commented:
How you've done a controlled randomized clinical trial by using a drug (misoprostol) that has been banned in Turkey since August 2012? When was this research done? I assume that you have done before 2012. Does this research have ethics committee approval? In the text you gave the dose of misoprostol 400 mg and on tables 400 microg, which is correct? Are vaginal and rectal forms of misoprostol in Turkey available? According to my knowledge misoprostol in Turkey is available only in oral form. How did you use a drug that is only available in oral form for vaginal and rectal usage? You should have to explain this in your text. Why did you use SPSS Version 10.0? This is a very old version of SPSS. Today version 23.0 is available. Could this study be a translation of the study which was presented at the 7th Uludag Gynecology and Obstetric Winter Congress in 2005 (7. Uludag Jinekoloji ve Obstetrik Kıs Kongresi, 2005) under the Turkish title “Postpartum Kanamanın Önlenmesinde Profilaktik Misoprostol Kullanımı Randomize Klinik Çalışma: Uncu G, Omak M, Karahasan M, Yılmaz A.” However the names of some authors are different in this Turkish study but the translation of the title from Turkish into English is same as your study: Prophylactic misoprostol for the prevention of postpartum hemorrhage: a randomized controlled trial
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
On 2017 Dec 08, Nazan Bilgel commented:
How you've done a controlled randomized clinical trial by using a drug (misoprostol) that has been banned in Turkey since August 2012? When was this research done? I assume that you have done before 2012. Does this research have ethics committee approval? In the text you gave the dose of misoprostol 400 mg and on tables 400 microg, which is correct? Are vaginal and rectal forms of misoprostol in Turkey available? According to my knowledge misoprostol in Turkey is available only in oral form. How did you use a drug that is only available in oral form for vaginal and rectal usage? You should have to explain this in your text. Why did you use SPSS Version 10.0? This is a very old version of SPSS. Today version 23.0 is available. Could this study be a translation of the study which was presented at the 7th Uludag Gynecology and Obstetric Winter Congress in 2005 (7. Uludag Jinekoloji ve Obstetrik Kıs Kongresi, 2005) under the Turkish title “Postpartum Kanamanın Önlenmesinde Profilaktik Misoprostol Kullanımı Randomize Klinik Çalışma: Uncu G, Omak M, Karahasan M, Yılmaz A.” However the names of some authors are different in this Turkish study but the translation of the title from Turkish into English is same as your study: Prophylactic misoprostol for the prevention of postpartum hemorrhage: a randomized controlled trial
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY. -
On 2017 Dec 16, Y Uncu commented:
We would like to state that this comment might be misleading for the readers, since the issues mentioned in the comment has been previously brought into question and extensively evaluated. It was concluded that there is no scientific flaw accordingly. We would be glad to provide further information should the readers require. (yuncu@uludag.edu.tr)
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-